FDA Approves Subcutaneous Induction Regimen for AbbVie's Skyrizi (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

Oct 27, 2026 - 07:00
 0  0
NORTH CHICAGO, Ill., Oct. 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for Skyrizi (risankizumab-rzaa) for adults with moderately to severely...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0